|Bid||3.48 x 1200|
|Ask||3.79 x 2900|
|Day's Range||3.3300 - 4.1400|
|52 Week Range||3.3300 - 25.2900|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
WESTLAKE VILLAGE, Calif., Dec. 06, 2018 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that.
Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the Company’s lead drug candidate developed using its proprietary Topical by Design™ platform. This Phase 2b study, in mild-to-moderate psoriasis patients with at least moderate pruritus (itch), was designed to assess the efficacy and safety of SNA-120 on itch (primary endpoint), as well as the underlying psoriasis (secondary endpoints). In this study, subjects treated with SNA-120 (0.05%) achieved statistical significance, compared to vehicle, on important pre-specified regulatory endpoints of psoriasis disease severity. Subjects treated with SNA-120 also experienced a meaningful reduction in itch, although the result did not reach statistical significance against vehicle.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
WESTLAKE VILLAGE, Calif., Nov. 08, 2018 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Social Reality Inc (NASDAQ: SRAX ) stock was trading ...
Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its acne treatment did not meet their main goals of reducing inflammatory lesions on patients' skin. Sienna, which went public about ...